Novartis AG’s latecomer anti-PD1 immunotherapy candidate spartalizumab has failed its first big test: a Phase III study in melanoma where used together with the company’s marketed BRAF/MEK combination, Tafinlar plus Mekinist.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?